The Patented Medicine Prices Review Board (PMPRB) tabled its 2006 Annual Report before Parliament on July 18. The mandate of the PMPRB is to review and analyze the pricing of patented medicines in Canada and to take remedial action when necessary.

In its 2006 Annual Report, the PMPRB reported that a total of 1181 patented drug products for human use were under the PMPRB's jurisdiction in 2006. These included ninety nine (99) new drug products, of which 29 medicines were new active ingredients. As of March 31, 2007, the PMPRB had reviewed 79 new drug products, of which 68 were considered to be within the PMPRB Guidelines, while 11 are the subject of further investigations.

Please find below links to the 2006 Annual Report and a Communiqué issued by the PMPRB:É__200638KSD-7192007-4352.pdf